TF and neoplasm: The WGS-based ctDNA assay used in our study does not have low sensitivity (a major concern with liquid biopsy-based assessments of MRD38,39), but our results suggest that isolated detection of ctDNA in WW patients with a highly sensitive primary-tumor-informed assay is not a sufficient predictor of regrowth and should be combined with dynamic monitoring of TF.